ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

European Heart Journal
John J P KasteleinMichel Farnier

Abstract

To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia (HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT). In two randomized, double-blind studies (ODYSSEY FH I, n = 486; FH II, n = 249), patients were randomized 2 : 1 to alirocumab 75 mg or placebo every 2 weeks (Q2W). Alirocumab dose was increased at Week 12 to 150 mg Q2W if Week 8 LDL-C was ≥1.8 mmol/L (70 mg/dL). Primary endpoint (both studies) was percentage change in calculated LDL-C from baseline to Week 24. Mean LDL-C levels decreased from 3.7 mmol/L (144.7 mg/dL) at baseline to 1.8 mmol/L (71.3 mg/dL; -57.9% vs. placebo) at Week 24 in patients randomized to alirocumab in FH I and from 3.5 mmol/L (134.6 mg/dL) to 1.8 mmol/L (67.7 mg/dL; -51.4% vs. placebo) in FH II (P < 0.0001). These reductions were maintained through Week 78. LDL-C <1.8 mmol/L (regardless of cardiovascular risk) was achieved at Week 24 by 59.8 and 68.2% of alirocumab-treated patients in FH I and FH II, respectively. Adverse events resulted in discontinuation in 3.4% of alirocumab-treated patients in FH I (vs. 6.1% placebo) and 3.6% (vs. 1.2%) in FH II. Rate of injection site reactions in alirocumab-treated p...Continue Reading

References

Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Mar 23, 2012·The New England Journal of Medicine·Evan A SteinGary D Swergold
Mar 15, 2014·Circulation Research·Nabil G SeidahMajambu Mbikay
Mar 19, 2014·Journal of the American College of Cardiology·Rodrigo AlonsoUNKNOWN SAFEHEART Investigators
Mar 17, 2015·The New England Journal of Medicine·Jennifer G RobinsonUNKNOWN ODYSSEY LONG TERM Investigators

❮ Previous
Next ❯

Citations

Aug 18, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Eliano P NavareseMarco Matteo Ciccone
Jan 5, 2016·European Heart Journal·M John ChapmanUlf Landmesser
Feb 9, 2016·Cell Metabolism·Daniel J Rader
Jan 2, 2016·Atherosclerosis·Christina Reith, Jane Armitage
Mar 8, 2016·Revista Española De Cardiología·Iván J Núñez-GilRosa María Lidón
Mar 8, 2016·Journal of Atherosclerosis and Thrombosis·Sang-Hak Lee
Mar 19, 2016·Journal of the American College of Cardiology·Robert A Hegele
Sep 4, 2015·European Heart Journal·Ulrich Laufs, Klaus G Parhofer
Mar 26, 2016·The Lancet. Diabetes & Endocrinology·Ezim Ajufo, Daniel J Rader
May 18, 2016·The American Journal of Cardiology·Tamio TeramotoMarie Thérèse Baccara-Dinet
May 3, 2016·European Heart Journal·Thomas F Lüscher
Jun 2, 2016·The Lancet. Diabetes & Endocrinology·Raul D SantosUNKNOWN International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
Jun 5, 2016·Mayo Clinic Proceedings·Maya S Safarova, Iftikhar J Kullo
Jun 11, 2016·European Heart Journal·Thomas F Lüscher
Jul 17, 2016·Postgraduate Medicine·Marc S SabatineSeth J Baum
Aug 3, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Anthony S Wierzbicki, Paul Grant
Aug 9, 2016·Cardiovascular Research·Giuseppe Danilo NorataAlberico L Catapano
Sep 14, 2016·The American Journal of Cardiology·Peter P Toth
Oct 13, 2016·The American Journal of Cardiology·Peter H JonesJennifer G Robinson
Oct 30, 2016·The American Journal of Cardiology·Daniel GaudetFrederick J Raal
Aug 2, 2016·British Journal of Clinical Pharmacology·Ioanna Gouni-BertholdWinfried März
Oct 21, 2016·Journal of Internal Medicine·J C Cohen
Oct 16, 2016·International Journal of Clinical Practice·Terry McCormackMark Blagden
Mar 24, 2017·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Martin Prøven BogsrudKirsten B Holven
Jan 14, 2017·International Urology and Nephrology·P PavlakouM Elisaf
Feb 1, 2018·International Journal of Molecular Sciences·Eswar Kandaswamy, Li Zuo
Apr 19, 2018·The Annals of Pharmacotherapy·Roshni S PatelOludamilola Olugbile
Mar 16, 2017·World Journal of Cardiology·Rahul ChaudharyAndrew Sumner
Jun 8, 2018·Journal of Atherosclerosis and Thrombosis·Mariko Harada-ShibaUNKNOWN Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia
Aug 3, 2018·Journal of Atherosclerosis and Thrombosis·Tamio TeramotoUNKNOWN ODYSSEY Japan Investigators
Aug 24, 2018·Journal of Atherosclerosis and Thrombosis·Makoto KinoshitaUNKNOWN Committee for Epidemiology and Clinical Management of Atherosclerosis
Dec 17, 2015·Circulation. Cardiovascular Genetics·Markey C McNutt, Zahid Ahmad
Aug 11, 2019·Current Topics in Medicinal Chemistry·Bo ChenPengjun Zhao
Oct 16, 2016·Coronary Artery Disease·John J P KasteleinMichel Farnier

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Clinical Trials Mentioned

NCT01663402

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.